-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Xilio Therapeutics, editor of WuXi AppTec's content team, announced today that it has reached a clinical trial cooperation agreement with Merck & Co.
(MSD) to evaluate its tumor-selective research anti-CTLA-4 monoclonal antibody XTX101, and Merck’s anti-PD-1 therapy Keytruda ( Pembrolizumab) combined with the safety and efficacy of the treatment of patients with solid tumors.
Although monoclonal antibodies targeting CTLA-4 have achieved significant curative effects in a variety of cancer types, their large side effects limit its application as a combination therapy.
The XTX101 developed by Xilio is a tumor-selective anti-CTLA-4 antibody designed to precisely limit the anti-CTLA-4 effect within the tumor and prevent peripheral effects outside the tumor.
This strategy may improve the therapeutic index and overcome the limitations of efficacy and tolerability of other anti-CTLA-4 antibodies.
In preclinical studies, XTX101 was well tolerated and achieved strong tumor growth inhibition, including complete remission through tumor selective immune activation.
"The clinical benefit of targeting CTLA-4 as a cancer treatment has been recognized.
However, the combination therapy of anti-CTLA-4 antibodies and PD-1 checkpoint inhibitors is associated with stronger toxicity, preventing patients from receiving effective doses of anti-CTLA -4 antibody," said Dr.
Marty Huber, Chief Medical Officer of Xilio Therapeutics, "We believe that tumor-selective immuno-oncology has the potential to provide meaningful treatments for patients with many different cancers.
I am very happy to work with Merck to study this combination and work hard.
Improve treatment options for cancer patients."Xilio Therapeutics plans to submit an IND application to the US FDA in the second quarter of this year.
If approved, it will immediately start a phase 1 clinical trial of XTX101 as a single agent and in combination with Keytruda for the treatment of solid tumors.
References: [1] Xilio Therapeutics Announces Clinical Trial Collaboration With Merck on Anti-CTLA-4 Monoclonal Antibody Program.
Retrieved May 25, 2021, fromNote: This article aims to introduce the progress of medical and health research, not Recommended treatment plan.
If you need treatment plan guidance, please go to a regular hospital for treatment.
(MSD) to evaluate its tumor-selective research anti-CTLA-4 monoclonal antibody XTX101, and Merck’s anti-PD-1 therapy Keytruda ( Pembrolizumab) combined with the safety and efficacy of the treatment of patients with solid tumors.
Although monoclonal antibodies targeting CTLA-4 have achieved significant curative effects in a variety of cancer types, their large side effects limit its application as a combination therapy.
The XTX101 developed by Xilio is a tumor-selective anti-CTLA-4 antibody designed to precisely limit the anti-CTLA-4 effect within the tumor and prevent peripheral effects outside the tumor.
This strategy may improve the therapeutic index and overcome the limitations of efficacy and tolerability of other anti-CTLA-4 antibodies.
In preclinical studies, XTX101 was well tolerated and achieved strong tumor growth inhibition, including complete remission through tumor selective immune activation.
"The clinical benefit of targeting CTLA-4 as a cancer treatment has been recognized.
However, the combination therapy of anti-CTLA-4 antibodies and PD-1 checkpoint inhibitors is associated with stronger toxicity, preventing patients from receiving effective doses of anti-CTLA -4 antibody," said Dr.
Marty Huber, Chief Medical Officer of Xilio Therapeutics, "We believe that tumor-selective immuno-oncology has the potential to provide meaningful treatments for patients with many different cancers.
I am very happy to work with Merck to study this combination and work hard.
Improve treatment options for cancer patients."Xilio Therapeutics plans to submit an IND application to the US FDA in the second quarter of this year.
If approved, it will immediately start a phase 1 clinical trial of XTX101 as a single agent and in combination with Keytruda for the treatment of solid tumors.
References: [1] Xilio Therapeutics Announces Clinical Trial Collaboration With Merck on Anti-CTLA-4 Monoclonal Antibody Program.
Retrieved May 25, 2021, fromNote: This article aims to introduce the progress of medical and health research, not Recommended treatment plan.
If you need treatment plan guidance, please go to a regular hospital for treatment.
